NIOSH Hazardous Drugs
Repackaged by Safecor Health and compliant with USP <800>
The National Institute for Occupational Safety and Health (NIOSH) considers a drug to be hazardous if it exhibits at least one of the following criteria: carcinogenicity, teratogencicity or developmental toxicity, reproductive toxicity, organ toxicity at low doses, genotoxicity, or structure and toxicity profiles of new drugs that mimic existing hazardous drugs.
Safecor Health will repackage the following drugs defined as hazardous on the NIOSH list.
Table 1:Antineoplastics
|
Table 2:Non-Antineoplastic(one or more criteria) |
Table 3:Non-Antineoplastic(reproductive effects) |
| abiraterone | abacavir | acitretin |
| anastrozole | carbamazepine | ambrisentan |
| bicalutamide | contraceptives | bosentan |
| enzalutamide | cyclosporine | cabergoline |
| erlotinib | deferiprone | clonazepam |
| exemestane | divalproex | colchicine |
| flutamide | entecavir | dronedarone |
| letrozole | estrogen | dutasteride |
| megestrol | fluoxymesterone | ergonovine |
| tamoxifen | leflunomide | eslicarbazepine |
| medroxyprogesterone acetate | finasteride | |
| methimazole | fluconazole | |
| mycophenolate | methylergonovine | |
| nevirapine | methyltestosterone | |
| oxcarbazepine | misoprostol* | |
| paliperidone | paroxetine | |
| phenoxybenzamine | ribavirin | |
| phenytoin | temazepam | |
| progesterin | testosterone | |
| propylthiouracil | topiramate | |
| raloxifene | valproate/valproic acid | |
| rasagiline | voriconazole | |
| sirolimus | warfarin | |
| spironolactone | ziprasidone | |
| tacrolimus | zoledronic acid | |
| teriflunomide | zonisamide | |
| valganciclovir | ||
| zidovudine |
*Full tabs only. Cannot repackage half or quarter tabs.
Contact us for more information on our packaging capabilities.
